TY - JOUR ID - 87411 TI - TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Mohammed Basabaeen, Ameen Abdulaziz AU - Abdelgader, Enaam Abdalrhman AU - Babekir, Ebtihal Ahmed AU - Abdelrahim, Saadia Osman AU - Eltayeb, Nada Hassan AU - Altayeb, Osama Ali AU - Fadul, Eman Abbass AU - Sabo, Abdulwali AU - Ibrahim, Ibrahim Khider AD - Department of Haematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan. AD - Department of Pathology, Faculty of Medicine, Al Neelain University, Khartoum, Sudan. AD - Department of Physiology, Faculty of Medicine, Al Neelain University, Khartoum, Sudan. AD - Flow Cytometry Laboratory for Leukemia &Lymphoma Diagnosis, Khartoum, Sudan. AD - Department of Statistics, School of Medical Sciences, University Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia. Y1 - 2019 PY - 2019 VL - 20 IS - 5 SP - 1579 EP - 1585 KW - CLL KW - TP53 Gene KW - SNP KW - 72 Arg/Pro Polymorphism KW - risk DO - 10.31557/APJCP.2019.20.5.1579 N2 - Objective: This study aimed at exploring the association of TP53 72Arg/Pro polymorphism and Risk of ChronicLymphocytic Leukemia and to assess the correlation between TP53 72Arg/Pro polymorphism and clinical parameter,hematological profile and some biological prognostic markers among Sudanese patients with chronic lymphocyticleukemia. Methods: A case-control study was conducted in Khartoum state, Sudan, during the period from April 2017 toApril 2018, involved 110 B-CLL patients and 80 healthy volunteers as a control group. Physical examination, CompleteBlood Count and Immunophenotype were performed in all patients to confirm the diagnosis. Clinical staging such asRai and Binet were studied. CD38 and ZAP70 were performed by Flow Cytometry. Blood samples were collected fromall participants; DNA was extracted by using ANALYTIKJENA Blood DNA Extraction Kit (Germany) and analyzedTP53 codon 72Arg/Pro Polymorphism by using AS-PCR. The statistical analysis was performed using SPSS version23.0 software (Chicago, IL, USA). Results: the Arg/Pro was the most frequent genotype in B-CLL patients(50%),followed by Arg/Arg (25.5%) and Pro/Pro (24.5%), whereas in healthy control group Arg/Pro was the most frequent(47.5%), followed by Arg/Arg (45%) and Pro/Pro (7.5%). Our data indicate a higher frequency of homozygous Pro/Pro in the B-CLL patients as compared to controls with an OR of 4.01 for the Pro/Pro genotype and lower frequencyof Arg/Arg genotype in CLL patients as compared to controls with an OR of .42 for the Arg/Arg genotype. Also, thePro allele showed higher risk than Arg allele (P value=0.000, OR 2.23, 95% CI=1.45-3.41). No significant associationbetween gender, clinical staging systems (Rai, Binet), biological prognostic markers (CD38 expression or ZAP70expression), and TP53 codon 72Arg/Pro polymorphisms, except Arg/Arg genotype tended to be associated with youngerage (P =0.04). Conclusion: Our data suggested that Pro/Pro genotype contribute to increased susceptibility to B-ChronicLymphocytic Leukemia risk in our population tenfold higher than those had Arg/Arg genotype UR - https://journal.waocp.org/article_87411.html L1 - https://journal.waocp.org/article_87411_d0d8a54f228d83c439bde772f88657ad.pdf ER -